The test is now authorized for use with anterior nasal swab samples in addition to the previously authorized throat and nasopharyngeal samples.

Last week, readers were most interested in a story about WHO's update to its operational handbook for diagnosing tuberculosis.

The submission releases $1.3 million in US funding support from the Biomedical Advanced Research and Development Authority (BARDA), the firm said.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage ...

The company's Acute Respiratory Distress and Pneumonia test is a PCR-based assay for the detection and differentiation of about 100 causes of infections.

The firm said that it will use the money for working capital and general corporate purposes, and the raise follows a $3.25 million public offering that closed in May.

The firm's goal for its SeekIt platform is to combine the accessibility of antibody and antigen testing and the accuracy of PCR for use in low-resource settings.

The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple entities as well as other in vitro diagnostic tests.

The technology can more effectively test for antibiotic susceptibility in heteroresistant bacterial populations than existing approaches.

The firm performed 2,756 EsoGuard tests during the quarter and initiated testing and billing under its first commercial insurance coverage policy.

ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

The new ruling reverses a jury verdict from four years ago that handed ArcherDx, which no longer exists, $4.7 million in damages.